Indian contract drug manufacturer Suven Pharmaceuticals (SUVH.NS), opens new tab said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its contract and development manufacturing services (CDMO) business. Private equity firm Advent International wholly owns Cohance and has a significant stake in Suven Pharma, which was demerged from its parent entity Suven Life Sciences (SUVP.NS), in 2020. The combined entity, which Advent has been looking to merge since 2022, will be 66.7% owned by Advent’s entities and the remaining 33.3% will be held by public shareholders, the company said.
Read the full article: India’s Suven Pharma, Cohance Merge to Boost Contract Drug Manufacturing Services //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/indias-suven-pharma-cohance-merge-boost-contract-drug-manufacturing-services-2024-02-29